Treatment of Liver Disorders with Ursodeoxycholic Acid and Rifaximin

Ursodeoxycholic Acid (UDCA) Therapy

The American Association for the Study of Liver Diseases recommends UDCA as the first-line treatment for primary biliary cirrhosis at doses of 13-15 mg/kg/day 1
UDCA at 13-15 mg/kg/day significantly decreases serum bilirubin, alkaline phosphatase, cholesterol, and immunoglobulin M levels in primary biliary cirrhosis patients 1
Long-term UDCA treatment delays histological progression of primary biliary cirrhosis when started at an early stage of the disease 1
UDCA treatment is associated with a significant reduction in liver transplantation or death in patients with moderate to severe primary biliary cirrhosis 1
The British Society of Gastroenterology recommends against routine use of UDCA for newly diagnosed primary sclerosing cholangitis due to limited efficacy 1
High-dose UDCA (>20 mg/kg/day) has been associated with worse outcomes in primary sclerosing cholangitis and should be avoided 2
UDCA has beneficial effects in intrahepatic cholestasis of pregnancy at doses of 10-15 mg/kg/day 1
UDCA is generally well tolerated, although nausea and mild dizziness may occur in up to 25% of patients 1
UDCA is considered safe during pregnancy and breastfeeding 1

Rifaximin is effective for the treatment of pruritus in primary biliary cirrhosis 3

Regular monitoring of liver biochemistry is essential to assess treatment response to UDCA 1
AMA-positive individuals with normal liver tests should undergo annual reassessment of biochemical markers of cholestasis 1
UDCA has not demonstrated significant effects on symptoms like fatigue or pruritus in primary biliary cirrhosis, so additional treatments may be needed for symptom management 1

Alkaline phosphatase elevation appears earlier than hyperbilirubinemia in cholestatic conditions, making it a sensitive early marker, and gamma-glutamyl transferase (GGT) also elevates early alongside alkaline phosphatase 4
Alkaline phosphatase and GGT are the earliest cholestasis markers 4

Combined analysis of randomized controlled trials demonstrates improved transplantation-free survival in patients with primary biliary cirrhosis treated with UDCA, enabling a longer transplantation-free interval and prolonging disease survival 5, 6, 7